Alfasigma Gains Positive CHMP Opinion for Filgotinib in axSpA
MILAN, Italy — September 18, 2026 Alfasigma announced that the Committee for Medicinal Products for Human Use (CHMP) of...
Ulcerative Colitis
Advertisement
Accro Bioscience Advances AC-101 in Ulcerative Colitis
New York, United States, September 20, 2026 Accro Bioscience has announced that the first patient has been dosed in...
Spyre Therapeutics Advances SPY003 in UC with Positive Phase 2 Data
WALTHAM, Mass. — September 8, 2026 Spyre Therapeutics announced positive 12-week induction results from Part A of the Phase...
Alvotech Wins FDA Review Acceptance for AVT80 Biosimilar
Reykjavik, Iceland – August 31, 2026 Alvotech announced that the U.S. FDA has accepted for review its Biologics License...
Tvardi Therapeutics Highlights TTI-109 Potential in Ulcerative Colitis
HOUSTON, Texas, August 12, 2026 Tvardi Therapeutics, Inc. announced that it will host a key opinion leader (KOL) webinar...
Advertisements
Photys Therapeutics and Polymed Begin Phase 1 Trial of PHT-776
WALTHAM, Massachusetts, and HANGZHOU, China, August 13, 2026 Photys Therapeutics, Inc. and Polymed Biopharmaceuticals, Inc. announced the initiation of...
Palisade Bio Advances PALI-2108 Into Phase 2 IBD Trials
DENVER, Colorado, August 10, 2026 Palisade Bio, Inc. announced its second-quarter 2026 financial results and provided a business update...
Fresenius Kabi’s Vedolizumab Biosimilar Accepted for FDA and EMA Review
BAD HOMBURG, Germany, July 31, 2026 Fresenius Kabi, an operating company of Fresenius, announced that both the U.S. Food...
Polpharma Biologics Secures FDA and EMA Review for PB016
ROTKREUZ, Switzerland, July 31, 2026 Polpharma Biologics International AG announced that the U.S. Food and Drug Administration (FDA) and...
Abivax Aligns with FDA on Obefazimod NDA Submission
PARIS, France, July 30, 2026 Abivax SA announced the successful completion of a positive pre-New Drug Application (pre-NDA) interaction...
Advertisement
